Katherine Bowdish - MyoKardia Director
Director
Dr. Katherine S. Bowdish Ph.D. is Director of the company. since August 2014. Dr. Bowdish is Vice President of Global RD and Head of Sunrise at Sanofi S.A. She joined Sanofi in February 2013 to launch the Sunrise initiative following extensive experience in cofounding and leading early stage biotechnology companies including transactions involving financings partnering and MA. Immediately prior to joining Sanofi Dr. Bowdish led Cambridgebased Permeon Biologics Inc. developing a novel approach to intracellular delivery of biological therapies as its president and chief science officer from January 2012 to February 2013. Prior to Permeon Dr. Bowdish cofounded and served as president and chief executive officer of Anaphore Inc. a platformbased drug development company with a focus on trivalent biological therapies from December 2007 to June 2011. Dr. Bowdish was previously president of Alexion Antibody Technologies Inc. from September 2000 to December 2006 and senior vice president of Alexion Pharmaceuticals Inc. upon leading the acquisition of Prolifaron Inc. by Alexion from March 2001 to December 2006. She was the founder chief executive officer and chief science officer of Prolifaron from May 1997 to September 2000 a privately held antibody discovery company that grew through large pharmaceutical partnerships and ultimately an acquisition. In earlier years Dr. Bowdish worked with Richard A. Lerner M.D. at The Scripps Research Institute on catalytic antibodies and related antibody technologies and at Monsanto Company in agricultural biotechnology. Dr. Bowdish holds a Ph.D. from Columbia University College of Physicians and Surgeons and a B.A. from the College of William and Mary. Dr. Bowdishs qualifications to serve on our board of directors include her significant experience in building and leading successful biotechnology companies and her scientific expertise. since 2014.
| Age | 57 |
| Tenure | 10 years |
| Phone | 650 741-0900 |
| Web | www.myokardia.com |
MyoKardia Management Efficiency
The company has return on total asset (ROA) of (23.07) % which means that it has lost $23.07 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (42.7) %, meaning that it created substantial loss on money invested by shareholders. MyoKardia's management efficiency ratios could be used to measure how well MyoKardia manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 51.61 M in liabilities with Debt to Equity (D/E) ratio of 0.06, which may suggest the company is not taking enough advantage from borrowing. MyoKardia has a current ratio of 17.62, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist MyoKardia until it has trouble settling it off, either with new capital or with free cash flow. So, MyoKardia's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like MyoKardia sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for MyoKardia to invest in growth at high rates of return. When we think about MyoKardia's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Alexander Cappello | The Cheesecake Factory | 62 | |
| Jose Rojas | Fomento Economico Mexicano | 66 | |
| Mariana Gonda | Fomento Economico Mexicano | 50 | |
| Cecil Conlee | National Beverage Corp | 80 | |
| Christopher Sarles | Willamette Valley Vineyards | 49 | |
| Consuelo Garza | Fomento Economico Mexicano | 84 | |
| Laurence Mindel | The Cheesecake Factory | 80 | |
| David Pittaway | The Cheesecake Factory | 66 | |
| Peter Browning | ScanSource | 76 | |
| John Reilly | ScanSource | 69 | |
| Jose Hernando | Fomento Economico Mexicano | 79 | |
| Mary Gentry | ScanSource | N/A | |
| Gary Fayard | Monster Beverage Corp | 66 | |
| Michael Larson | Fomento Economico Mexicano | 61 | |
| Stanley Turel | Willamette Valley Vineyards | 66 | |
| Francisco Carbajal | Fomento Economico Mexicano | 65 | |
| Jonathan Ricci | Willamette Valley Vineyards | N/A | |
| Mark Vidergauz | Monster Beverage Corp | 63 | |
| Max Gonzalez | Fomento Economico Mexicano | 49 | |
| Barbara Laguera | Fomento Economico Mexicano | 56 | |
| Ricardo Escajadillo | Fomento Economico Mexicano | 67 | |
Management Performance
| Return On Equity | -42.7 | |||
| Return On Asset | -23.07 |
MyoKardia Leadership Team
Elected by the shareholders, the MyoKardia's board of directors comprises two types of representatives: MyoKardia inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MyoKardia. The board's role is to monitor MyoKardia's management team and ensure that shareholders' interests are well served. MyoKardia's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MyoKardia's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Eric Topol, Independent Director | ||
| Sunil Agarwal, Independent Director | ||
| Christine MD, Co-Founder | ||
| Taylor Harris, CFO | ||
| Mark Perry, Independent Director | ||
| June Lee, COO | ||
| Cynthia Ladd, General Counsel | ||
| William Fairey, Executive Vice President and Chief Commercial Officer | ||
| Wendy Yarno, Independent Director | ||
| Kevin Starr, Director | ||
| Jake Bauer, Vice President - Business Development and Business Operations | ||
| Joseph Lambing, Senior Vice President - Nonclinical and Pharmaceutical Development | ||
| Steven Chan, Vice President Corporate Controller | ||
| Mary Cranston, Director | ||
| Katherine Bowdish, Director | ||
| Robert McDowell, Sr. VP of Drug Discovery | ||
| David Meeker, Independent Director | ||
| Marc Semigran, Chief Medical Officer | ||
| Leslie Leinwand, Co-Founder | ||
| Tassos Gianakakos, CEO and President and Director | ||
| Charles Homcy, Director | ||
| Jonathan Fox, Chief Medical Officer | ||
| Kimberly Popovits, Independent Director |
MyoKardia Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is MyoKardia a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -42.7 | |||
| Return On Asset | -23.07 | |||
| Current Valuation | 11.15 B | |||
| Shares Outstanding | 53.32 M | |||
| Shares Owned By Insiders | 2.22 % | |||
| Shares Owned By Institutions | 94.59 % | |||
| Number Of Shares Shorted | 4.63 M | |||
| Price To Earning | (57.57) X | |||
| Price To Book | 14.19 X | |||
| Price To Sales | 253.61 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in MyoKardia Stock
If you are still planning to invest in MyoKardia check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MyoKardia's history and understand the potential risks before investing.
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |